In this episode of Healthcare Logic for Growth, we break down what healthcare startups need to do to succeed - and why so many fail. We cover the five biggest success factors, including solving a real problem, proving outcomes, building the payment model early, fitting into clinical workflows, and scaling with trust. We also look at five common failure patterns, including weak validation, no reimbursement path, long sales cycles, poor workflow fit, and trust breakdowns.

We use real-world examples from Omada Health, Oshi Health, Zocdoc, Theranos, and Babylon Health to show what success and failure look like in practice. If you’re building, investing in, or marketing to healthcare startups, this episode is a practical guide to what actually matters. Key Topics - Why healthcare startups are different from consumer tech. - The five things a healthcare startup needs to do to succeed. - The five most common reasons healthcare startups fail. - Lessons from real companies with public-facing data. - Questions founders should ask to stay on track. - A go-forward strategy for building a durable healthcare company.

Sources Referenced in This Episode:

- AMA case study on Omada Health, highlighting evidence-based care, data-powered coaching, connected devices, and care coordination.

- Omada public platform information on outcomes and care delivery.

- AMA and related public materials on Oshi Health, including multidisciplinary GI care, outcomes, and cost savings.

- Zocdoc’s public milestone update on profitability, cash flow, provider growth, and business model improvements.

- STAT’s analysis of why healthcare startups fail, especially around reimbursement, pricing, and operational complexity.

- Public materials on Theranos’s failures and regulatory issues.

- Public reporting and analysis on Babylon Health’s collapse and reimbursement challenges.

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve.

Visit https://lifesciencelogic.com/ or reach us at Eric@lifesciencelogic.com.

Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic

The MFN drug pricing framework - what began as voluntary agreements with sixteen of the largest pharmaceutical companies - is now moving toward mandatory rules that will reach smaller biotechs and pharma companies. At the same time, a 100% pharmaceutical tariff takes effect September 29th for smaller manufacturers, with a lower 20% rate available only to companies that have engaged the MFN framework and filed domestic manufacturing plans.

BIO International opens at the same time of this published episode, June 22nd. So, in this episode, we flip the script: instead of treating MFN as a threat, we show small life science companies how to turn it into a commercial advantage - with five specific actions you can take starting this week.

Sources Referenced in This Episode:

Skadden Arps — "MFN Drug Pricing and Impact on International Life Sciences Licensing Deals" — June 1, 2026

BioTech Briefings / Gibson Dunn — "MFN Drug Pricing in 2026: Voluntary Deals Are Giving Way to Mandatory Rules" — March 2026

Clinical Leader — "U.S. Pharma Tariffs and MFN Become Law After April 2 Update" — April 2026

AJMC — "MFN Drug Pricing Proposal Raises Questions Around Access, Innovation, and Commercial Coverage" — June 2026

BioSpace — "Despite MFN Deals, Drug Pricing Will Dog Pharma Into 2026"

PharmExec — "What the Most Favored Nation Executive Order Means to Pharma Brands and Future Implications" — April 2026

BIO International Convention 2026 — San Diego, June 22–25, 2026 — convention.bio.org

White House Council of Economic Advisers — "Savings from Most-Favored-Nation Drug Pricing Policy" — May 2026

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve.

Visit https://lifesciencelogic.com/ or reach us at Eric@lifesciencelogic.com.

Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic

Healthcare is full of great products that never became great businesses. In this first episode of the Healthcare Startup Revenue Series, we break down 4 of the structural barriers that accelerate performance:

• Buyer vs. user separation
• Long purchasing cycles
• The evidence requirement
• Economic model misalignment

Whether you’re still in your first year of commercial activity or stuck at early customers and unable to scale, this episode gives you a foundation to consider.

Sources Referenced:

• Rock Health Digital Health Funding Report - https://rockhealth.com/
• HIMSS Healthcare Procurement Stakeholder Research - https://www.himss.org/
• Health Care Transformation Task Force - Value-Based Care Contracting Frameworks - https://hcttf.org/

About Life Science Logic:

Life Science Logic helps hospitals, HHAs, healthcare associations, small life science and healthcare companies go to market smarter, not more expensively. We combine commercial strategy, competitive intelligence, and planning with a disciplined, cost-conscious approach - delivering the rigor of a top-tier consultancy without the expanded overhead. The result? Our clients cut unnecessary spending, improve commercial efficiency, and give better performance earlier.

Ready to spend less and perform better? Learn more at https://lifesciencelogic.com/ or reach us at Eric@lifesciencelogic.com.

Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic